Top

Molecular Cancer

Published in:

Open Access 01-12-2005 | Research

Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and Caveolin-1

Authors: Min Lin, Melinda M DiVito, Sofia D Merajver, Madanamohan Boyanapalli, Kenneth L van Golen

Published in: Molecular Cancer | Issue 1/2005

Abstract

Background

In the current study we investigated the role of caveolin-1 (cav-1) in pancreatic adenocarcinoma (PC) cell migration and invasion; initial steps in metastasis. Cav-1 is the major structural protein in caveolae; small Ω-shaped invaginations within the plasma membrane. Caveolae are involved in signal transduction, wherein cav-1 acts as a scaffolding protein to organize multiple molecular complexes regulating a variety of cellular events. Recent evidence suggests a role for cav-1 in promoting cancer cell migration, invasion and metastasis; however, the molecular mechanisms have not been described. The small monomeric GTPases are among several molecules which associate with cav-1. Classically, the Rho GTPases control actin cytoskeletal reorganization during cell migration and invasion. RhoC GTPase is overexpressed in aggressive cancers that metastasize and is the predominant GTPase in PC. Like several GTPases, RhoC contains a putative cav-1 binding motif.

Results

Analysis of 10 PC cell lines revealed high levels of cav-1 expression in lines derived from primary tumors and low expression in those derived from metastases. Comparison of the BxPC-3 (derived from a primary tumor) and HPAF-II (derived from a metastasis) demonstrates a reciprocal relationship between cav-1 expression and p42/p44 Erk activation with PC cell migration, invasion, RhoC GTPase and p38 MAPK activation. Furthermore, inhibition of RhoC or p38 activity in HPAF-II cells leads to partial restoration of cav-1 expression.

Conclusion

Cav-1 expression inhibits RhoC GTPase activation and subsequent activation of the p38 MAPK pathway in primary PC cells thus restricting migration and invasion. In contrast, loss of cav-1 expression leads to RhoC-mediated migration and invasion in metastatic PC cells.

Available only for authorised users

Fujimoto T, Kogo H, Nomura R, Une T: Isoforms of caveolin-1 and caveolar structure. J Cell Sci. 2000, 113 Pt 19: 3509-3517.PubMed

Okamoto T, Schlegel A, Scherer PE, Lisanti MP: Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem. 1998, 273: 5419-5422. 10.1074/jbc.273.10.5419CrossRefPubMed

Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP: Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem. 1996, 271: 9690-9697. 10.1074/jbc.271.16.9690CrossRefPubMed

Gingras D, Gauthier F, Lamy S, Desrosiers RR, Beliveau R: Localization of RhoA GTPase to endothelial caveolae-enriched membrane domains. Biochem Biophys Res Commun. 1998, 247: 888-893. 10.1006/bbrc.1998.8885CrossRefPubMed

Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG, Lisanti MP: Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem. 2000, 275: 20717-20725. 10.1074/jbc.M909895199CrossRefPubMed

Fiucci G, Ravid D, Reich R, Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene. 2002, 21: 2365-2375. 10.1038/sj.onc.1205300CrossRefPubMed

Lu Z, Ghosh S, Wang Z, Hunter T: Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003, 4: 499-515. 10.1016/S1535-6108(03)00304-0CrossRefPubMed

Sloan EK, Stanley KL, Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene. 2004, 23: 7893-7897. 10.1038/sj.onc.1208062CrossRefPubMed

Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP: Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004, 279: 51630-51646. 10.1074/jbc.M409214200CrossRefPubMed

10.

Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM: Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol. 2002, 161: 1647-1656.PubMedCentralCrossRefPubMed

11.

Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M, Hayakawa M: Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol. 2004, 172: 718-722. 10.1097/01.ju.0000130943.23317.08CrossRefPubMed

12.

Bender FC, Reymond MA, Bron C, Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 2000, 60: 5870-5878.PubMed

13.

Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, Katoh H: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer. 2002, 87: 1140-1144. 10.1038/sj.bjc.6600619PubMedCentralCrossRefPubMed

14.

Wu C, Butz S, Ying Y, Anderson RG: Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane. J Biol Chem. 1997, 272: 3554-3559. 10.1074/jbc.272.6.3554CrossRefPubMed

15.

Gleizes PE, Noaillac-Depeyre J, Dupont MA, Gas N: Basic fibroblast growth factor (FGF-2) is addressed to caveolae after binding to the plasma membrane of BHK cells. Eur J Cell Biol. 1996, 71: 144-153.PubMed

16.

Bilderback TR, Grigsby RJ, Dobrowsky RT: Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae. J Biol Chem. 1997, 272: 10922-10927. 10.1074/jbc.272.16.10922CrossRefPubMed

17.

Li S, Couet J, Lisanti MP: Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996, 271: 29182-29190. 10.1074/jbc.271.46.29182CrossRefPubMed

18.

Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP: Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem. 1995, 270: 15693-15701. 10.1074/jbc.270.26.15693CrossRefPubMed

19.

Raftopoulou M, Hall A: Cell migration: Rho GTPases lead the way. Dev Biol. 2004, 265: 23-32. 10.1016/j.ydbio.2003.06.003CrossRefPubMed

20.

del Peso L, Hernandez-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C, Lacal JC: Rho proteins induce metastatic properties in vivo. Oncogene. 1997, 15: 3047-3057. 10.1038/sj.onc.1201499CrossRefPubMed

21.

Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000, 406: 532-535. 10.1038/35020106CrossRefPubMed

22.

Carr KM, Bittner M, Trent JM: Gene-expression profiling in human cutaneous melanoma. Oncogene. 2003, 22: 3076-3080. 10.1038/sj.onc.1206448CrossRefPubMed

23.

Marionnet C, Lalou C, Mollier K, Chazal M, Delestaing G, Compan D, Verola O, Vilmer C, Cuminet J, Dubertret L, Basset-Seguin N: Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development. Oncogene. 2003, 22: 3500-3505. 10.1038/sj.onc.1206571CrossRefPubMed

24.

Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest. 2003, 83: 861-870.CrossRefPubMed

25.

Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003, 9: 2632-2641.PubMed

26.

Shinto E, Tsuda H, Matsubara O, Mochizuki H: [Significance of RhoC expression in terms of invasion and metastasis of colorectal cancer]. Nippon Rinsho. 2003, 61 Suppl 7: 215-219.PubMed

27.

Wang W, Yang LY, Yang ZL, Huang GW, Lu WQ: Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol. 2003, 9: 1950-1953.PubMed

28.

Kondo T, Sentani K, Oue N, Yoshida K, Nakayama H, Yasui W: Expression of RHOC is associated with metastasis of gastric carcinomas. Pathobiology. 2004, 71: 19-25. 10.1159/000072958CrossRefPubMed

29.

Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukumoto M: Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer. 1998, 77: 147-152.PubMedCentralCrossRefPubMed

30.

Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, Lemoine NR: Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene. 2002, 21: 4587-4594. 10.1038/sj.onc.1205570CrossRefPubMed

31.

Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003, 63: 2649-2657.PubMed

32.

van Golen KL: Inflammatory Breast Cancer: Relationship between growth factor signaling and motility in aggressive cancers. Breast Cancer Research. 2003, 5: 174- 10.1186/bcr598PubMedCentralCrossRefPubMed

33.

Lin M, van Golen KL: Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat. 2003

34.

Aktories K, Hall A: Botulinum ADP-ribosyltransferase C3: a new tool to study low molecular weight GTP-binding proteins. Trends Pharmacol Sci. 1989, 10: 415-418. 10.1016/0165-6147(89)90191-0CrossRefPubMed

35.

Aktories K, Braun U, Rosener S, Just I, Hall A: The rho gene product expressed in E. coli is a substrate of botulinum ADP-ribosyltransferase C3. Biochem Biophys Res Commun. 1989, 158: 209-213. 10.1016/S0006-291X(89)80199-8CrossRefPubMed

36.

Couet J, Belanger MM, Roussel E, Drolet MC: Cell biology of caveolae and caveolin. Adv Drug Deliv Rev. 2001, 49: 223-235. 10.1016/S0169-409X(01)00139-9CrossRefPubMed

37.

Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP: Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem. 1997, 272: 6525-6533. 10.1074/jbc.272.48.30429CrossRefPubMed

38.

Engelman JA, Zhang XL, Razani B, Pestell RG, Lisanti MP: p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J Biol Chem. 1999, 274: 32333-32341. 10.1074/jbc.274.45.32333CrossRefPubMed

39.

Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP: Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 1998, 428: 205-211. 10.1016/S0014-5793(98)00470-0CrossRefPubMed

40.

van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD: Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis. 2002, 19: 301-311. 10.1023/A:1015518114931CrossRefPubMed

41.

Yip-Schneider MT, Lin A, Marshall MS: Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun. 2001, 280: 992-997. 10.1006/bbrc.2001.4243CrossRefPubMed

42.

Berger DH, Jardines LA, Chang H, Ruggeri B: Activation of Raf-1 in human pancreatic adenocarcinoma. J Surg Res. 1997, 69: 199-204. 10.1006/jsre.1997.5022CrossRefPubMed

43.

Ilangumaran S, Hoessli DC: Effects of cholesterol depletion by cyclodextrin on the sphingolipid microdomains of the plasma membrane. Biochem J. 1998, 335 ( Pt 2): 433-440.CrossRef

44.

Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci U S A. 1995, 92: 1381-1385.PubMedCentralCrossRefPubMed

45.

Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP: Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem. 1997, 272: 16374-16381. 10.1074/jbc.272.26.16374CrossRefPubMed

46.

Razani B, Schlegel A, Liu J, Lisanti MP: Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans. 2001, 29: 494-499. 10.1042/BST0290494CrossRefPubMed

47.

Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC: Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 2001, 61: 4386-4392.PubMed

48.

Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, Kao SY: The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med. 2003, 32: 461-467. 10.1034/j.1600-0714.2003.00185.xCrossRefPubMed

49.

Bockhorn M, Roberge S, Sousa C, Jain RK, Munn LL: Differential gene expression in metastasizing cells shed from kidney tumors. Cancer Res. 2004, 64: 2469-2473.CrossRefPubMed

50.

Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol. 2003, 22: 469-480.PubMed

51.

Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, Tsao MS: Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000, 157: 1623-1631.PubMedCentralCrossRefPubMed

52.

Liu N, Furukawa T, Kobari M, Tsao MS: Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol. 1998, 153: 263-269.PubMedCentralCrossRefPubMed

53.

van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD: RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia. 2000, 2: 418-425. 10.1038/sj.neo.7900115PubMedCentralCrossRefPubMed

54.

van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000, 60: 5832-5838.PubMed

55.

Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD: Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol. 2002, 160: 579-584.PubMedCentralCrossRefPubMed

56.

Evers EE, van der Kammen RA, ten Klooster JP, Collard JG: Rho-like GTPases in tumor cell invasion. Methods Enzymol. 2000, 325: 403-415.CrossRefPubMed

57.

Diekmann D, Hall A: In vitro binding assay for interactions of Rho and Rac with GTPase- activating proteins and effectors. Methods Enzymol. 1995, 256: 207-215.CrossRefPubMed

58.

Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ: A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett. 1987, 38: 137-147. 10.1016/0304-3835(87)90209-6CrossRefPubMed

Title: Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and Caveolin-1
Authors: Min Lin
Melinda M DiVito
Sofia D Merajver
Madanamohan Boyanapalli
Kenneth L van Golen
Publication date: 01-12-2005
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2005
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-4-21

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2005

Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer

Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome

Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation

Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential

Attenuated Expression of DFFB is a Hallmark of Oligodendrogliomas with 1p-Allelic Loss

Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer